Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab Monotherapy in Moderate to Severe Atopic Dermatitis (ECZTRA 1)
NCT03131648Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of tralokinumab in atopic dermatitis (AD) (6 arms), sponsored by LEO Pharma. Primary endpoints: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at 16 weeks and Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index at 16 weeks. Started May 2017; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03131648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131648.